Why the study?
Does propofol provide adequate seizure duration and similar safety profiles compared to methohexital in patients undergoing ECT?
Does propofol provide adequate seizure duration and similar safety profiles compared to methohexital in patients undergoing ECT?
Answers are grounded in this paper and cite their sources.
Lower-dose propofol appears to be an acceptable alternative to methohexital for ECT induction, though further studies on clinical outcome are needed.
Comment: ECT is becoming increasingly popular in the management of depressive disorders that are refractory to pharmacologic intervention. Historically, the objective of ECT was to induce a generalized tonic-clonic seizure of at least 20–30 sec duration. It appears, however, that the relationship between the therapeutic efficacy of ECT and cerebral seizure activity is controversial. A second measure of the clinical efficacy of ECT is said to be related to the cumulative seizure time, but this dogma, too, has recently been challenged. Until recently, methohexital had been virtually unchallenged as the most popular induction agent for ECT, because of its short duration of action and minimal effect on seizure threshold. Moreover, methohexital purportedly was associated with the lowest incidence of cardiac dysrhythmias induced by ECT. Despite potential advantages, including a more favorable recovery profile, propofol administration during ECT has been discouraged because of the unfavorable effects of induction does of propofol on seizure duration. The effect of drugs on seizure duration appears to be dose related. Mean propofol doses of 1.3–1.6 mg/kg were used in earlier studies that demonstrated significantly shorter seizure duration. By reducing the dose of propofol to 0.75 mg/kg, Fredman et al. report absolute and cumulative seizure durations considered adequate even by previously accepted (read questionable) standards, as did Koffel et al.1 using mean propofol doses of 1.09 mg/kg. Interestingty, Koffel et al., using no premedication and using hard-copy continuous ECT recording, reported that propofol had a similar incidence of ECT-induced dysrhythmias (95%) compared with methohexital (dose range, 0.5–1.0 mg/kg). The latter group of investigators also reported no significant difference in recovery time between the two drugs. Fredman et al. admit that their study may be criticized for using equal, but not necessarily equivalent, doses of methohexital and propofol. In addition, they note that the randomized cross-over study design precludes an overall assessment of the effect of the anesthetic on patient outcome. A more definitive study would examine clinical outcome in a large number of depressed patients receiving equivalent doses of propofol or methohexital for all of their ECT treatments. Although it appears that 0.75 mg/kg propofol is an acceptable alternative to methohexital for ECT, additional studies are needed to ascertain the effect of propofol on efficiency and outcome.
No takes yet. Share an insight, caveat, or question.
Fredman et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: